Similarities in the Neuropathy Phenotype of Cancer Survivors Who Received Different Classes of Chemotherapy Drugs
- PMID: 35533976
- DOI: 10.1016/j.jpain.2022.04.007
Similarities in the Neuropathy Phenotype of Cancer Survivors Who Received Different Classes of Chemotherapy Drugs
Abstract
With the advent of platinum and taxane compounds used as single agents or in combination regimens, survival rates for some of the most common cancers have improved substantially. However, information on differences in the chemotherapy-induced peripheral neuropathy (CIPN) phenotype among single and combination regimens is limited. Study's purposes were to evaluate for differences in demographic and clinical characteristics; subjective and objective measures of CIPN; as well as the severity of common symptoms and quality of life among survivors who received platinum- (n = 95), taxane- (n = 200), or platinum and taxane-containing (n = 131) regimens. Patients completed self-report questionnaires (ie, duration of CIPN, pain intensity, pain qualities, pain interference) and underwent a physical examination that evaluated light touch, pain, and cold sensations and balance. For most of the subjective and objective measures of CIPN, as well as symptom severity and quality of life scores, no differences were found among the 3 chemotherapy groups. In all 3 chemotherapy treatment groups, CIPN was a painful, small fiber, and length dependent neuropathy. These findings support the hypothesis that CIPN induced by different classes of chemotherapy, as single agents or in combination, produce a similar CIPN phenotype which raises the possibility that CIPN induced by diverse chemotherapy protocols has the same underlying mechanism. PERSPECTIVE: In this study, that compared patients who received only platinum, only taxane, or both platinum and taxane containing regimens, no differences were found among the 3 groups in the CIPN phenotype. Findings raise the possibility that CIPN induced by diverse chemotherapy protocols has the same underlying mechanism.
Keywords: Balance; cancer; chemotherapy; pain; peripheral neuropathy; platinum; survivors; taxane.
Copyright © 2022 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.Support Care Cancer. 2019 Oct;27(10):3905-3912. doi: 10.1007/s00520-019-04695-3. Epub 2019 Feb 15. Support Care Cancer. 2019. PMID: 30770977 Free PMC article.
-
The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.JAMA Neurol. 2016 Jul 1;73(7):860-6. doi: 10.1001/jamaneurol.2016.0383. JAMA Neurol. 2016. PMID: 27183099 Free PMC article.
-
Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo.Med Sci Monit. 2022 Aug 31;28:e937856. doi: 10.12659/MSM.937856. Med Sci Monit. 2022. PMID: 36042691 Free PMC article.
-
Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review.J Cancer Surviv. 2023 Feb;17(1):222-236. doi: 10.1007/s11764-021-00988-x. Epub 2021 Jan 12. J Cancer Surviv. 2023. PMID: 33438175
-
Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.Acta Oncol. 2015 May;54(5):587-91. doi: 10.3109/0284186X.2014.995775. Epub 2015 Mar 9. Acta Oncol. 2015. PMID: 25751757 Review.
Cited by
-
Risk factors and screening for neurocognitive impacts of therapy.Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):259-265. doi: 10.1182/hematology.2022000409. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485082 Free PMC article.
-
Barriers and facilitators for participation in brain magnetic resonance imaging (MRI) scans in cancer research: a feasibility and acceptability analysis.Support Care Cancer. 2025 May 24;33(6):497. doi: 10.1007/s00520-025-09549-9. Support Care Cancer. 2025. PMID: 40411642
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical